| abstract |
Compounds of formula (I), physiologically acceptable salts and solvates thereof, wherein X is -O- or NR 5, Y is -N (R 5) R 4, -C (= NR 7) -NHR 7 or -C (= NR 9) -NHR 7, B is H or (a) R is H, A, cycloalkyl, Ar, arylalkyl or Pol, R1 is -OR or -N (R) 2, R2 and R3 are independently H, A, Hal, -NO2, -OR, -N (R) 2, CN, -COR, -SO 3 R, -SO 2 R, -NHC (O) A or -SR, R 4 is H, R 7, -C (= NR 7) -NHR 7, -C (= NR 9) -NHR 7, -C (= CH-NO 2) -NHR 7 or Het, R 5 and R 5 'are independently H or A, R 6 is Hal or -NO 2, R 7 is H, -C (O) R 8, -C (O) ) Ar, R 8, -COOR 8, -COO (CH 2) o -Ar; -SO 2 -Ar, -SO 2 R 8 or -SO 2 Het, R 8 is A or cycloalkyl, R 9 is -CN or -NO 2, A is C 1 -C 8 alkyl, where the alkyl may be optionally mono- or polysubstituted and / or the carbon chain is -O - interrupted by atoms, Ar is phenyl, naphthyl, anthryl or biphenylyl, each of which is unsubstituted or mono-, di- or tri-substituted with A, -OH, -OA, -CN, -NO2 or Hal, cycloalkyl is C3-C15-cycloalkyl. , Hal is F, Cl, Br or I, Het is a saturated, partially unsaturated or fully unsaturated monocyclic or bicyclic 5-10 membered heterocyclic group which may be represented by 1 or 2 N and / or 1 or 2 S or O atoms and the heterocyclic group optionally mono- or di-substituted with = O, A, -NO 2, -NHCOA- or -NHA, Pol represents a solid phase in the functional n is independently selected from 1, 2, 3, 4, 5 or 6, o is 1, 2, 3, or 4, p is 1, 2, 3, 4, or 5. for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, coronary heart disease or atherosclerosis. HE |